临床医学工程
臨床醫學工程
림상의학공정
CLINICAL MEDICAL ENGINEERING
2014年
8期
1017-1018
,共2页
不同剂量%阿托伐他汀%老年冠心病%不良反应%安全性%可行性
不同劑量%阿託伐他汀%老年冠心病%不良反應%安全性%可行性
불동제량%아탁벌타정%노년관심병%불량반응%안전성%가행성
Different dose%Atorvastatin%Senile coronary heart disease%Adverse reactions%Safety%Feasibility
目的：对不同剂量阿托伐他汀治疗老年冠心病患者的安全性及可行性进行分析和探讨。方法选择2011年10月到2013年10月在本院进行治疗的老年冠心病患者68例，随机将其分为A组和B组两组各34例，A组患者在治疗中给予40mg阿托伐他汀，B组患者在治疗中给予20mg阿托伐他汀，在治疗过程中对两组患者的不良症状发生情况进行观察，并在治疗结束后对其血脂情况进行比较。结果经治疗后两组患者的HDL-C水平均有一定程度的升高，TG、TC以及LDL-C水平均有一定程度的下降，两组患者治疗前后相比差异具有统计学意义(均有P<0.05)；治疗后两组患者相比A组HDL-C升高水平明显高于B组，且TG、TC以及LDL-C下降水平明显低于B组，两组相比差异具有统计学意义(均有P<0.05)；在不良反应发生中，A组患者与B组患者表现ALT>3个正常上限(ULN)各1例，停药复查后恢复正常，发生率均为2.94%，两组发生率相比差异无统计学意义(P>0.05)。A组有6例患者在治疗1~2个月出现心绞痛症状，发生率为17.65%(6/34)，B组有5例患者在治疗1~3个月出现心绞痛症状，发生率为14.71%(5/34)，两组发生率相比差异无统计学意义(P>0.05)。结论大剂量阿托伐他汀应用于老年冠心病的治疗中疗效优于小剂量阿托伐他汀，且两种方式安全性无差异，故在临床治疗中建议采用大剂量给药。
目的：對不同劑量阿託伐他汀治療老年冠心病患者的安全性及可行性進行分析和探討。方法選擇2011年10月到2013年10月在本院進行治療的老年冠心病患者68例，隨機將其分為A組和B組兩組各34例，A組患者在治療中給予40mg阿託伐他汀，B組患者在治療中給予20mg阿託伐他汀，在治療過程中對兩組患者的不良癥狀髮生情況進行觀察，併在治療結束後對其血脂情況進行比較。結果經治療後兩組患者的HDL-C水平均有一定程度的升高，TG、TC以及LDL-C水平均有一定程度的下降，兩組患者治療前後相比差異具有統計學意義(均有P<0.05)；治療後兩組患者相比A組HDL-C升高水平明顯高于B組，且TG、TC以及LDL-C下降水平明顯低于B組，兩組相比差異具有統計學意義(均有P<0.05)；在不良反應髮生中，A組患者與B組患者錶現ALT>3箇正常上限(ULN)各1例，停藥複查後恢複正常，髮生率均為2.94%，兩組髮生率相比差異無統計學意義(P>0.05)。A組有6例患者在治療1~2箇月齣現心絞痛癥狀，髮生率為17.65%(6/34)，B組有5例患者在治療1~3箇月齣現心絞痛癥狀，髮生率為14.71%(5/34)，兩組髮生率相比差異無統計學意義(P>0.05)。結論大劑量阿託伐他汀應用于老年冠心病的治療中療效優于小劑量阿託伐他汀，且兩種方式安全性無差異，故在臨床治療中建議採用大劑量給藥。
목적：대불동제량아탁벌타정치료노년관심병환자적안전성급가행성진행분석화탐토。방법선택2011년10월도2013년10월재본원진행치료적노년관심병환자68례，수궤장기분위A조화B조량조각34례，A조환자재치료중급여40mg아탁벌타정，B조환자재치료중급여20mg아탁벌타정，재치료과정중대량조환자적불량증상발생정황진행관찰，병재치료결속후대기혈지정황진행비교。결과경치료후량조환자적HDL-C수평균유일정정도적승고，TG、TC이급LDL-C수평균유일정정도적하강，량조환자치료전후상비차이구유통계학의의(균유P<0.05)；치료후량조환자상비A조HDL-C승고수평명현고우B조，차TG、TC이급LDL-C하강수평명현저우B조，량조상비차이구유통계학의의(균유P<0.05)；재불량반응발생중，A조환자여B조환자표현ALT>3개정상상한(ULN)각1례，정약복사후회복정상，발생솔균위2.94%，량조발생솔상비차이무통계학의의(P>0.05)。A조유6례환자재치료1~2개월출현심교통증상，발생솔위17.65%(6/34)，B조유5례환자재치료1~3개월출현심교통증상，발생솔위14.71%(5/34)，량조발생솔상비차이무통계학의의(P>0.05)。결론대제량아탁벌타정응용우노년관심병적치료중료효우우소제량아탁벌타정，차량충방식안전성무차이，고재림상치료중건의채용대제량급약。
Objective To analyze and discuss the feasibility and safety of different doses of atorvastatin in the treatment of elderly patients with coronary artery disease. Methods 68 elderly patients with coronary heart disease in our hospital from October 2011 to October 2013 were selected and randomly divided into two groups, with 34 cases in each group. Patients in the group A were treated with Atorvastatin 40 mg, while patients in group B were treated with Atorvastatin 20 mg. The complication during therapy and the blood fat after therapy were compared between two groups. Results After treatment, the HDL-C level increased, and TG, TC and LDL-C levels decreased in both group, and the differences were statistically significant (P<0.05);The differences of TG, TC and LDL-C after treatment between two groups were statistically significant (P <0.05). Both groups had 1 case (2.94%) of ALT more than 3 times of upper limits of normal (ULN), and both cases returned to normal after drug withdrawal. 6 cases (17.65%) of group A had symptom of angina pectoris at the first one to two months of treatment, while 5 cases (14.71%) of group B had symptom of angina pectoris at the first one to three months of treatment (P>0.05). Conclusions For elderly patients with coronary artery disease, the clinical effect of high dose of atorvastatin is better than that of small dose of atorvastatin, and there is no difference in the safety between two doses. So, we suggest high dose in clinic.
